PACB Quote, Financials, Valuation and Earnings

Clearpoint Neuro, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -66.48%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Clearpoint Neuro, Inc.'s return on equity of -105.19%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.36, signalling upside risk potential of 25.38%. On the other hand Clearpoint Neuro, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 100.14%. Given that Clearpoint Neuro, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Clearpoint Neuro, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison Clearpoint Neuro, Inc. has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.79800000000001%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearpoint Neuro, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Clearpoint Neuro, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Clearpoint Neuro, Inc. quarterly revenues of $8.9M. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than Clearpoint Neuro, Inc.'s net income of -$5.9M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Clearpoint Neuro, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 3.66x versus 11.82x for Clearpoint Neuro, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -0.63%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat ICU Medical, Inc.'s return on equity of -0.36%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.36, signalling upside risk potential of 25.38%. On the other hand ICU Medical, Inc. has an analysts' consensus of $180.83 which suggests that it could grow by 23.03%. Given that Pacific Biosciences of California, Inc. has higher upside potential than ICU Medical, Inc., analysts believe Pacific Biosciences of California, Inc. is more attractive than ICU Medical, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison ICU Medical, Inc. has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.719%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. ICU Medical, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are smaller than ICU Medical, Inc. quarterly revenues of $537.7M. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than ICU Medical, Inc.'s net income of -$3.4M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while ICU Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 3.66x versus 1.56x for ICU Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of -735.19%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.36, signalling upside risk potential of 25.38%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 133.91%. Given that Intellia Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are larger than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Pacific Biosciences of California, Inc.'s net income of -$38M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 3.66x versus 17.47x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -98.85% compared to Pacific Biosciences of California, Inc.'s net margin of 17.41%. Pacific Biosciences of California, Inc.'s return on equity of -218.65% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Pacific Biosciences of California, Inc. has a consensus price target of $2.36, signalling upside risk potential of 25.38%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 24.96%. Given that Pacific Biosciences of California, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Pacific Biosciences of California, Inc. is more attractive than West Pharmaceutical Services, Inc..

Pacific Biosciences of California, Inc. has a beta of 2.319, which suggesting that the stock is 131.863% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Pacific Biosciences of California, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Pacific Biosciences of California, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pacific Biosciences of California, Inc. quarterly revenues are $38.4M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Pacific Biosciences of California, Inc.'s net income of -$38M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Pacific Biosciences of California, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 40.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacific Biosciences of California, Inc. is 3.66x versus 6.68x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.